Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · Awarded
- Buyer
- NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
- Status
- Awarded
- Country
- United Kingdom
- Region
- England
- Sector
- Manufacturing
- Reference
- FaT-ocds-h6vhtk-02bcb3
- Published
- 2021-06-16
Tender summary
All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. Due to considerable increase in the demand for the test the AWMGL intends to award a two year contract (for a period of 12 months with the option to extend for…
This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.
Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.
Register for full access